abstract |
RNAi (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA gene (apo (a)) are described. Also described are pharmaceutical compositions containing one or more RNA and LPA agents, optionally with one or more additional drugs. In vivo delivery of the disclosed RNAi LPA agents to liver cells provides inhibition of LPA gene expression and treatment of cardiovascular diseases and diseases associated with the cardiovascular system. |